12
Jan
2026
Sovereign Risk: The Geopolitical Price of Outsourcing the Biotech Engine
On the surface, delegates at this year’s JP Morgan Healthcare Conference have reason to be pleased. The Nasdaq Biotech Index was up 30% last year. After years of public market woes, it looks like there is light at the end of the tunnel. Some structural issues still exist – 10 years to get a molecule to clinic, regulators that need... Read More